{"id":"batch-2-of-mcv4","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"MCV4 works by introducing a small, harmless piece of the meningococcal bacteria to the body, which triggers an immune response and helps the body produce antibodies to fight the infection. This immune response provides long-term protection against meningococcal disease. The vaccine is typically administered as a single dose or a booster dose to individuals who have previously received the vaccine.","oneSentence":"MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:12.232Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT06131554","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Menhycia"],"phase":"phase_3","status":"active","brandName":"batch 2 of MCV4","genericName":"batch 2 of MCV4","companyName":"CanSino Biologics Inc.","companyId":"cansino-biologics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"MCV4 is a vaccine that stimulates the body's immune response to the meningococcal conjugate serogroups A, C, W, and Y. Used for Active immunization against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}